Martin S. Maron, Steve R. Ommen
doi : 10.1161/CIRCULATIONAHA.120.051330
Circulation. 2021 | Volume 143, Issue 12: 1181–1183
Sean Agbor-Enoh, Palak Shah, Ilker Tunc, Steven Hsu, Stuart Russell, Erika Feller, Keyur Shah, Maria E. Rodrigo, Samer S. Najjar, Hyesik Kong, Mehdi Pirooznia, Ulgen Fideli, Alfiya Bikineyeva, Argit Marishta, Kenneth Bhatti, Yanqin Yang, Cedric Mutebi, Kai Yu, Moon Kyoo Jang, Charles Marboe, Gerald J. Berry, Hannah A. Valantine and For the GRAfT Investigators
doi : 10.1161/CIRCULATIONAHA.120.049098
Circulation. 2021 | Volume 143, Issue 12: 1184–1197
After heart transplantation, endomyocardial biopsy (EMBx) is used to monitor for acute rejection (AR). Unfortunately, EMBx is invasive, and its conventional histological interpretation has limitations. This is a validation study to assess the performance of a sensitive blood biomarker—percent donor-derived cell-free DNA (%ddcfDNA)—for detection of AR in cardiac transplant recipients.
Michelle M. Kittleson, Sonia Garg
doi : 10.1161/CIRCULATIONAHA.120.052925
Circulation. 2021 | Volume 143, Issue 12: 1198–1201
Christoph H?chsmann, James L. Dorling, Corby K. Martin, Robert L. Newton Jr, John W. Apolzan, Candice A. Myers, Kara D. Denstel, Emily F. Mire, William D. Johnson, Dachuan Zhang, Connie L. Arnold, Terry C. Davis, Vivian Fonseca, Carl J. Lavie, Eboni G. Price-Haywood, Peter T. Katzmarzyk and For the PROPEL Research Group
doi : 10.1161/CIRCULATIONAHA.120.051328
Circulation. 2021 | Volume 143, Issue 12: 1202–1214
Intensive lifestyle interventions (ILIs) are the first-line approach to effectively treat obesity and manage associated cardiometabolic risk factors. Because few people have access to ILIs in academic health centers, primary care must implement similar approaches for a meaningful effect on obesity and cardiometabolic disease prevalence. To date, however, effective lifestyle-based obesity treatment in primary care is limited. We examined the effectiveness of a pragmatic ILI for weight loss delivered in primary care among a racially diverse, low-income population with obesity for improving cardiometabolic risk factors over 24 months.
Ziad Hijazi, John H. Alexander, Zhuokai Li, Daniel M. Wojdyla, Roxana Mehran, Christopher B. Granger, Alexander Parkhomenko, M. Cecilia Bahit, Stephan Windecker, Ronald Aronson, Otavio Berwanger, Sigrun Halvorsen, Suzanne de Waha-Thiele, Peter Sinnaeve, Harald Darius, Robert F. Storey, Renato D. Lopes
doi : 10.1161/CIRCULATIONAHA.120.051020
Circulation. 2021 | Volume 143, Issue 12: 1215–1223
In the AUGUSTUS trial (An Open-Label, 2×2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban Versus Vitamin K Antagonist and Aspirin Versus Aspirin Placebo in Patients With Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Intervention), apixaban resulted in less bleeding and fewer hospitalizations than vitamin K antagonists, and aspirin caused more bleeding than placebo in patients with atrial fibrillation and acute coronary syndrome or percutaneous coronary intervention treated with a P2Y12 inhibitor. We evaluated the risk-benefit balance of antithrombotic therapy according to kidney function.
Wenzhu Li, Chase W. Kessinger, Makoto Orii, Hang Lee, Lang Wang, Ido Weinberg, Michael R. Jaff, Guy L. Reed, Peter Libby, Ahmed Tawakol, Peter K. Henke, Farouc A. Jaffer
doi : 10.1161/CIRCULATIONAHA.120.049096
Circulation. 2021 | Volume 143, Issue 12: 1224–1238
Up to 50% of patients with proximal deep vein thrombosis (DVT) will develop the postthrombotic syndrome characterized by limb swelling and discomfort, hyperpigmentation, skin ulcers, and impaired quality of life. Although catheter-based interventions enabling the restoration of blood flow (RBF) have demonstrated little benefit on postthrombotic syndrome, the impact on the acuity of the thrombus and mechanisms underlying this finding remain obscure. In experimental and clinical studies, we examined whether RBF has a restricted time window for improving DVT resolution.
Aaron W. Aday, Joshua A. Beckman
doi : 10.1161/CIRCULATIONAHA.120.052451
Circulation. 2021 | Volume 143, Issue 12: 1239–1241
Njabulo Ngwenyama, Annet Kirabo, Mark Aronovitz, Francisco Vel?zquez, Francisco Carrillo-Salinas, Ane M. Salvador, Tania Nevers, Venkataraman Amarnath, Albert Tai, Robert M. Blanton, David G. Harrison, Pilar Alcaide
doi : 10.1161/CIRCULATIONAHA.120.051889
Circulation. 2021 | Volume 143, Issue 12: 1242–1255
Despite the well-established association between T-cell–mediated inflammation and nonischemic heart failure, the specific mechanisms triggering T-cell activation during the progression of heart failure and the antigens involved are poorly understood. We hypothesized that myocardial oxidative stress induces the formation of isolevuglandin (IsoLG)–modified proteins that function as cardiac neoantigens to elicit CD4+ T-cell receptor (TCR) activation and promote heart failure.
doi : 10.1161/CIRCULATIONAHA.121.054326
Circulation. 2021 | Volume 143, Issue 12: 1256–1261
Tracy Hampton
doi : 10.1161/CIRCULATIONAHA.121.054218
Circulation. 2021 | Volume 143, Issue 12: 1262–1263
Zhaolong Xu, Qinghua Chang, Renguang Liu
doi : 10.1161/CIRCULATIONAHA.120.053436
Circulation. 2021 | Volume 143, Issue 12: 1264–1266
Won-Keun Kim, Thomas Walther, Christof Burgdorf, Helge M?llmann, Axel Linke, Simon Redwood, Christian Thilo, Michael Hilker, Michael Joner, Holger Thiele, Lars Conzelmann, Lenard Conradi, Sebastian Kerber, Gerhard Schymik, Bernard Prendergast, Oliver Husser, Johannes Blumenstein, Stefan Stortecky, Dik Heg, Arnaud Künzi, Peter Jüni, Stephan Windecker, Thomas Pilgrim, Jonas Lanz and For the SCOPE I Investigators
doi : 10.1161/CIRCULATIONAHA.120.052251
Circulation. 2021 | Volume 143, Issue 12: 1267–1269
Christian Saleh
doi : 10.1161/CIRCULATIONAHA.120.050617
Circulation. 2021 | Volume 143, Issue 12: e790–e791
doi : 10.1161/CIR.0000000000000970
Circulation. 2021 | Volume 143, Issue 12: e792–e793
doi : 10.1161/CIR.0000000000000975
Circulation. 2021 | Volume 143, Issue 12: e794
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟